55 results
Page 2 of 3
6-K
EX-99.2
ol5 lg69ca
10 Jan 22
InflaRx Announces New Pipeline Program – Oral C5aR Inhibitor
7:30am
6-K
EX-99.2
b0k1lovvwny
15 Nov 21
Current report (foreign)
7:36am
6-K
EX-99.2
2b5lokgvhkv04q4
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.2
8t6pr8vk7
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.2
uuxn2p
12 May 21
Current report (foreign)
4:30pm
6-K
EX-99.1
yf2ol0b2 ztoao8
1 Mar 21
Current report (foreign)
12:00am
424B5
dutu1j 0p
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
98ifm
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
y3y7t ygj
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
mc414ik52tb6fwnnzlr
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.2
hpkdh1
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.2
c1ipyrwo k1
30 Jul 20
Current report (foreign)
7:36am
424B5
jpf5h gsbdwh
20 Jul 20
Prospectus supplement for primary offering
9:21am
6-K
EX-99.1
nfhkali7
20 Jul 20
from 6-K
9:02am
F-3
9841vyuj
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.1
frthddsbu jhuimrk
30 Jun 20
Current report (foreign)
6:38am
6-K
EX-99.1
thewkf4f9lt7gfil9z
21 May 20
Current report (foreign)
8:09am
6-K
EX-99.2
xkjb3
21 May 20
Current report (foreign)
8:09am